Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Thermoregulatory Physiology of Menopausal Hot Flashes

NCT07824648 · tracked via the Priya Life Science USA tracker
Sponsor
SRI International
Phase
Not applicable
Started
2026-05-05
Last updated
2026-09-17

Condition(s) studied

Menopause Hot Flashes

Investigational drug(s) / intervention(s)

Intervention C (Targeted skin cooling)Intervention B (Ambient cooling)Intervention A (Room temperature)

Intervention C (Targeted skin cooling): Cooling targeted to the skin during a hot flash

Intervention B (Ambient cooling): Cooling of the room

Intervention A (Room temperature): Control condition (room temperature)

Study summary

This study is evaluating the effects of cooling on menopausal hot flashes in midlife women. Precise targeted cooling is provided to areas of the skin when a hot flash occurs.

Eligibility

Sex
FEMALE
Min age
40 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Female * Age range: 40 to 65 years and in menopausal transition or post-menopause; * At least 8 years of education to ensure adequate reading proficiency; * Primary language is English or Spanish. Exclusion Criteria: * History of medical or neurological illness or trauma that would affect the central nervous system (e.g., stroke, multiple sclerosis, epilepsy); * Current severe medical conditions (e.g. Diabetes, cancer, cardiovascular disease, renal or hepatic disease, thyroid disorders); * History of schizophrenia and/or bipolar disorder; * Dependence or abuse of illicit substances in the past year; * Current use of hormone therapy or other treatments for hot flash symptoms

Primary outcome measure(s)

  • Number of hot flashes — Across the ~5 hour experimental period in the lab
    Number of hot flashes, based on sternal skin conductance measurement

Trial sites (1)

FacilityCityRegionStatus
SRI International Menlo Park California Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07824648 on ClinicalTrials.gov ↗ ← All trials in the USA